PRA Health Sciences Inc

PRA Health Sciences — Q4 2016 Earnings Presentation

17 slides from PRA Health Sciences's earnings presentation, Feb 22, 2017

  1. Slide 1: Q4 2016 Earnings

    Q4 2016 Earnings February 22, 2017

  2. Slide 2: Forward Looking Statements and Use of Non-GAAP Financial Measures

    Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements that reflect, among other things, the Company’s current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and o

  3. Slide 3: Q4 2016 Highlights

    Q4 2016 Highlights ($ in millions, except per share amounts) $413.6 million of service revenue; 14.2% growth at actual foreign exchange rates and 14.6% constant currency growth $14.0 million of GAAP Net Income; Net Income per diluted share of $0.22 $45.9 million of Adjusted Net Income; Adjusted Net

  4. Slide 4: Trailing Quarterly Performance

    Trailing Quarterly Performance Adjusted Income from Operations ($M) Adjusted EBITDA Margin (%) Service Revenue ($M) Adjusted EBITDA ($M) $50.6 $56.2 $61.2 $62.4 $61.7 $67.4 $68.3 $67.8 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 16.8% 18.2% 19.3% 18.8% 18.1% 18.6% 18.7% 17.9% 15%

  5. Slide 5: Backlog and New Business Awards

    Backlog and New Business Awards Ending Backlog ($M) Backlog Conversion % Net Book-to-Bill Net New Business Awards ($M) 1.20 1.21 1.25 1.27 1.28 1.25 1.30 1.42 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 $398.0 $407.8 $431.4 $459.4 $476.2 $493.9 $519.1 $587.3 Q1 2015 Q2 2015 Q3 20

  6. Slide 6: Debt Structure

    Debt Structure * Covenant Net Debt is limited to $75 million in cash, with an additional limitation of $25 million of cash held by our foreign subsidiaries. Weighted Average ($ in millions) December 31, March 31, June 30, September 30, December 31, Interest Maturity 2015 2016 2016 2016 2016 Rate Dat

  7. Slide 7: FY 2017 and Q1 2017 Guidance

    FY 2017 and Q1 2017 Guidance FY 2017 Q1 2017 Low End of Range High End of Range Low End of Range High End of Range Service Revenue, in Millions $1,795.0 $1,835.0 $415.0 $425.0 GAAP Earnings per Diluted Share $2.46 $2.56 $0.41 $0.46 Adjusted Net Income per Diluted Share $3.08 $3.18 $0.57 $0.62 Annual

  8. Slide 8: Appendix

    Appendix PRAHEALTHSCIENCES

  9. Slide 9: Q4 and YTD 2016 Financial Results

    Q4 and YTD 2016 Financial Results ($ in millions, except per share amounts) 2016 2015 % Change 2016 2015 % Change Service Revenue 413.6 $ 362.3 $ 14.2% 1,580.0 $ 1,375.8 $ 14.8% EBITDA 54.3 $ 69.6 $ -22.0% 221.1 $ 251.5 $ -12.1% EBITDA Margin 13.1% 19.2% 14.0% 18.3% Adjusted EBITDA 73.9 $ 67.9 $ 8.8

  10. Slide 10: Trailing Quarterly Performance

    Trailing Quarterly Performance FY 16 v ($ in millions) FY 15 % Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Change Service Revenue 332.0 $ 336.5 $ 345.1 $ 362.3 $ 1,375.8 $ 372.3 $ 394.2 $ 399.8 $ 413.6 $ 1,580.0 $ 14.8% % growth Y-o-Y 6.6% 8.1% 7.8% 11.9% 8.6% 12.2% 17.2% 15.9% 14.2% 14.8% % growth Y-o-Y (constan

  11. Slide 11: Backlog and New Business Awards

    Backlog and New Business Awards FY 16 v ($ in millions) FY 15 % Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Change Beginning Backlog 2,141.1 $ 2,185.3 $ 2,262.4 $ 2,348.4 $ 2,141.1 $ 2,440.1 $ 2,552.8 $ 2,649.4 $ 2,775.6 $ 2,440.1 $ Ending Backlog 2,185.3 $ 2,262.4 $ 2,348.4 $ 2,440.1 $ 2,440.1 $ 2,552.8 $ 2,649.

  12. Slide 12: Reconciliation of GAAP Net Income to Adjusted EBITDA

    Reconciliation of GAAP Net Income to Adjusted EBITDA For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release ($ in millions) 2016 2015 2016 2015 Net income 14.0 $ 28.5 $ 68.2 $ 81.8 $ Depreciation and amortization

  13. Slide 13: Reconciliation of GAAP Net Income to Adjusted Net Income

    Reconciliation of GAAP Net Income to Adjusted Net Income For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release ($ in millions, except per share data) 2016 2015 2016 2015 Net income 14.0 $ 28.5 $ 68.2 $ 81.8 $ Amo

  14. Slide 14: Reconciliation of GAAP Income from Operations to Adjusted Income from Operations

    Reconciliation of GAAP Income from Operations to Adjusted Income from Operations For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release ($ in millions) 2016 2015 2016 2015 Income from operations 38.2 $ 43.9 $ 162.

  15. Slide 15: Geographic Breakdown

    Geographic Breakdown ($ in millions) Region Q4 16 Q4 15 US/Canada 241.8 214.3 Europe/Africa 132.6 112.1 Latin America 17.2 15.3 Asia/Pacific 21.9 20.6 Grand Total 413.6 362.3 60% 31% 4% 5% YTD 2016 Revenue 60% 31% 4% 5% YTD 2015 Revenue Region YTD 2016 YTD 2015 US/Canada 945.4 823.8 Europe/Africa 48

  16. Slide 16: Days Sales Outstanding

    Days Sales Outstanding ($ in millions) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Accounts Receivable, net 239.6 $ 281.4 $ 281.9 $ 288.3 $ 285.7 $ 320.6 $ 310.5 $ 283.4 $ Unbilled Services 132.8 115.2 118.5 126.8 134.4 142.8 136.6 155.6 Total Accounts Receivable and Unbilled Services 372.4 396.6 400.4 415.1 420.1 463.

  17. Slide 17: PRA Health Sciences

    m\/A ms PRAHEALTHSCIENCES HE FU RE OF CLINICAL DEVELOPME

PRA Health Sciences — Q4 2016 Earnings Presentation on 6ix